Today Stories
Leicester-based procurement services organisation Unimed Procurement Services (Unimed) has joined forces with International Health Partners (IHP) to create a long-lasting partnership dedicated to supplying life-saving medical supplies to countries in need.
In line with the two organisations’ mutual objective to increase accessibility to essential medical products and supplies to countries that are unable to access basic resources, the ongoing partnership involves several shipments of a variety of products donated by Unimed, a contribution worth $69,000.
As the largest coordinator of donated medical products in the UK and Europe, IHP works with a strong network of global healthcare industry donors, and will coordinate the placement and safe transport of the products to their in-country NGO…
-- DJS Antibodies' DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases
-- The company's proprietary HEPTAD platform will extend AbbVie's current discovery research capabilities by generating potential novel antibodies against difficult-to-drug protein targets in immunology and beyond
NORTH CHICAGO, Ill., Oct. 20, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS's lead program is DJS-002,…
Tübingen and Ingelheim, Germany, 20 October 2022 – University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world. Three to five fellowships will be awarded per year for up to three years with a target of nine to fifteen fellows in the program after five years.
The partners will define cutting-edge research topics at the intersection of health and applications of AI, which will be selected by a joint steering committee. First fellowships have been published here and interested post-doctoral candidates are invited to submit their applications.
Jan Nygaard Jensen, Global Head of Computational Biology and Digital Sciences…
Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide
Transaction valued at approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million
INDIANAPOLIS and BOSTON, Oct. 18, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
"We are honored to work with the talented team at Akouos who are breaking new ground in the science of trea…
Collaboration leverages one of world’s largest sources of de-identified patient data to accelerate drug discovery, initially in oncology
Access will enable GSK to improve clinical trial design, speed up enrolment and identify drug targets
GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data. Through its leading Artificial Intelligence and Machine Learning (AI/ML) capability, GSK will work together with Tempus to improve clinical trial design, speed up enrolment and identify drug targets. This will contribute to GSK’s R&D success rate and provide patients with more personalised treatment faste…
– Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123×CD3 DART® Molecule with Potential to Treat Various Hematologic Malignancies –
– Potential for Companies to Collaborate on Two Additional Future Research Programs –
FOSTER CITY, Calif. & ROCKVILLE, Md.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
This press…
Agreement key to building pan-European market access practice while underscoring a think global, act local commitment
Frankfurt, Germany – 13 October 2022: PharmaLex Group, the leading provider of specialised services for the pharma, biotech and MedTech industries worldwide, has announced a merger with UK pharmaceutical and healthcare services consultancy, NeoHealthHub Limited.
The agreement with NeoHealthHub (NHH), which was signed on Monday 10 October and which closes at the end of October, will be an important step in building a pan-European market access practice covering major markets, including the UK, Germany, Italy, Spain, France and the Nordics.
Founded in 2013, NHH supports its customers by offering innovative and comprehensive market access, data and capability developmen…
$97 million investment enhances bioanalytical services, helping pharma and biotech customers accelerate drug development
WILMINGTON, N.C.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia. The new unit will support increasing demand across biopharma for consistent, high-quality laboratory services to accelerate drug development. The 59,000-square-foot facility is part of the previously announced $97 million investment by the company to expand its bioanalytical laboratory operations in Richmond and add more than 500 jobs over the next three years.
The current laboratory services operation in Richmond, which Thermo Fisher acquired thro…
Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for Clients
MORRISVILLE, N.C. – October 11, 2022 – Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced an expanded partnership with Datavant, the leader in helping organizations securely connect health data. The increasing collaboration between the companies will further leverage the full suite of capabilities in Datavant Switchboard and Datavant’s large data ecosystem to accelerate the clinical development and commercialization of new therapies for patients.
Syneos Health and Datavant have a long-standing strategic partnership, and through this expanded relationship, Syneos Health will use Da…
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been named to Fortune’s 2022 Change the World list. The annual list recognizes companies that have had a positive social impact through activities that are part of their core business strategy. Merck was selected for its work expanding global access to the company’s human papillomavirus (HPV) vaccines.
“It’s an honor for Merck to be included on Fortune’s 2022 Change the World List, and recognized for making our HPV vaccines available to communities around the world,” said Robert M. Davis, chief executive officer and president, Merck. “This is the third time over the last five years that our company has been on this list and we are very proud of being acknowledged for the positive impac…
Leicester-based procurement services organisation Unimed Procurement Services (Unimed) has joined forces with International Health Partners (IHP) to create a long-lasting partnership dedicated to supplying life-saving medical supplies to countries in need.
In line with the two organisations’ mutual objective to increase accessibility to essential medical products and supplies to countries that are unable to access basic resources, the ongoing partnership involves several shipments of a variety of products donated by Unimed, a contribution worth $69,000.
As the largest coordinator of donated medical products in the UK and Europe, IHP works with a strong network of global healthcare industry donors, and will coordinate the placement and safe transport of the products to their in-country NGO…
Acquisition adds breakthrough calcitonin gene-related peptide portfolio, including NURTEC® ODT, to address needs of millions of migraine patients worldwide
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide (CGRP) receptor antagonists including:
Rimegepant:
Approved in the United States under the trade name NURTEC® ODT, in adults for both the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine
Approved in t…
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 3, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the completion of transactions that establish a long-term laboratory relationship with Ascension, one of the leading non-profit and Catholic health systems in the United States.
“Today’s announcement marks the beginning of an exciting chapter for both organizations, and for the patients, communities and clinicians we serve,” said Dr. Brian Caveney, chief medical officer and president of Labcorp Diagnostics. “We welcome those Ascension associates who will join Labcorp as a part of this strategic collaboration and look forward to working together to provide a smooth transition for patients, clinicians and employees.”
As a part of the companies’ strategic collaboration…
London, 28 September 2022 — Novartis Pharmaceuticals UK has today announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+.
Lifelight and PocDoc will receive support to scale their innovative digital solutions for cardiovascular disease (CVD) care. The companies were selected by a prestigious judging panel at the Novartis Biome UK Heart Health Catalyst 2022 Pitchfest, hosted at the Healthcare Excellence Through Technology (HETT) Show at ExCeL, London.
Through a world-first partnership spanning across industries, the Novartis Biome UK Heart Health Catalyst aims to transform CVD…
Modern name, purpose, and visual identity mark inspiring next chapter for maker of iconic, trusted brands, including Tylenol, Neutrogena, Listerine, and Band-Aid Brand
NEW BRUNSWICK, N.J. September 28, 2022 — Johnson & Johnson (the “Company”) (NYSE: JNJ) today took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company. The new corporate brand comes to life through a compelling purpose, and a timeless visual brand.
Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” referencing sight. With rich knowledge of human needs and deep consumer insights, Kenvue will deliver meaningful, per…
Quanticate, a global data-focused clinical research organisation (CRO), has partnered with leading cancer research organisation, Cancer Research UK, to launch the DETERMINE study which will test a range of therapies specifically targeting key genetic changes in cancer cells.
The first of its kind in the UK, the DETERMINE study will enrol patients with rare cancers, and aim to find out whether existing licensed drugs could be used to treat their type of cancer.
Cohorts will be formed of patients who have an identifiable genetic alteration in their cancer that can be targeted by treatments already approved for use in other cancer types.
Quanticate has been working with Cancer Research UK’s Centre for Drug Development to ensure the statistical design of the study is optimised.
“The study w…
LEIDEN, the Netherlands, September 26, 2022 / B3C newswire / -- SeraNovo BV (Leiden, The Netherlands) is pleased to announce the closing of a multi compound deal with Ildong Pharmaceutical (Seoul, South Korea), a pharmaceutical company engaged in the research and development of small molecules in the field of neuroscience and oncology.
Niall Hodgins, Chief Executive Officer of SeraNovo commented: “SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with Ildong.”
Link to the press release
A…
22-Sep-2022
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash. The acquisition provides Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed in early August 2022. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress a…
New facility adds supply assurance and capacity to enable more life-saving vaccines and therapies
WALTHAM, Mass., September 20, 2022 – Thermo Fisher Scientific Inc., the world leader in serving science, today opened a new biomanufacturing facility in Chelmsford, Massachusetts. The $160 million, 85,000-square-foot facility will help meet growing demand for the biologic materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s $650 million multi-year investment to expand its bioprocessing production capabilities.
The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines. These products help save time and reduce costs so that new treatments ca…
Significant investment will enable world-class discovery research, innovation in data science and digital health and collaborations in the Bay Area
BRISBANE, Calif., September 20, 2022 – Johnson & Johnson (NYSE: JNJ) (the Company) today opened its San Francisco Bay Campus, a state-of-the-art Research & Development (R&D) facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology. It will further integrate the…
